Skip to main content
OpenTrials
Completed

NCT Number: NCT03780062

Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.

No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Minor Traumatic Brain Injury Treatment by Antiplatelet

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU of MONTPELLIER, Montpellier, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 Years old
  • Minor traumatic brain injury measured by a Glasgow score between 13 and 15
  • Antiplatelet agent therapy
  • Free subject without tutorship or curatorship

Exclusion criteria

  • Age < 18 years old
  • Glasgow score <13
  • Traumatic brain injury older than 6 hours
  • Patient without any social security system
  • Patient with renforced protection (tutorship, curatorship, …)

Treatment and study plan

S100B protein dosing

Biological

Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L

Primary outcomes

  1. Brain scanner Detection of a cerebral lesion requiring a surgery or medical intervention or an hospitalisation for a patient who have serum level of S100B protein with the treshold of 0.105 μg/L

    Time frame: 3 hours

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Acronym: PETEChIA

Important dates

Study start
2019
Primary completion
2025
Study completion
2025
First posted
Dec 19, 2018
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.